Triple-negative breast cancer (TNBC) accounts for ∼20% of cases and contributes to basal and claudin-low molecular subclasses of the disease. TNBCs have poor prognosis, display frequent mutations in tumor suppressor gene p53 (TP53), and lack targeted therapies. The MET receptor tyrosine kinase is elevated in TNBC and transgenic Met models (Met mt ) develop basal-like tumors. To investigate collaborating events in the genesis of TNBC, we generated Met mt mice with conditional loss of murine p53 (Trp53) in mammary epithelia. Somatic Trp53 loss, in combination with Met mt , significantly increased tumor penetrance over Met mt or Trp53 loss alone. Unlike Met mt tumors, which are histologically diverse and enriched in a basal-like molecular signature, the majority of Met mt tumors with Trp53 loss displayed a spindloid pathology with a distinct molecular signature that resembles the human claudin-low subtype of TNBC, including diminished claudins, an epithelial-tomesenchymal transition signature, and decreased expression of the microRNA-200 family. Moreover, although mammary specific loss of Trp53 promotes tumors with diverse pathologies, those with spindloid pathology and claudin-low signature display genomic Met amplification. In both models, MET activity is required for maintenance of the claudin-low morphological phenotype, in which MET inhibitors restore cell-cell junctions, rescue claudin 1 expression, and abrogate growth and dissemination of cells in vivo. Among human breast cancers, elevated levels of MET and stabilized TP53, indicative of mutation, correlate with highly proliferative TNBCs of poor outcome. This work shows synergy between MET and TP53 loss for claudin-low breast cancer, identifies a restricted claudin-low gene signature, and provides a rationale for anti-MET therapies in TNBC.
Triple-negative breast cancer (TNBC) accounts for ∼20% of cases and contributes to basal and claudin-low molecular subclasses of the disease. TNBCs have poor prognosis, display frequent mutations in tumor suppressor gene p53 (TP53), and lack targeted therapies. The MET receptor tyrosine kinase is elevated in TNBC and transgenic Met models (Met mt ) develop basal-like tumors. To investigate collaborating events in the genesis of TNBC, we generated Met mt mice with conditional loss of murine p53 (Trp53) in mammary epithelia. Somatic Trp53 loss, in combination with Met mt , significantly increased tumor penetrance over Met mt or Trp53 loss alone. Unlike Met mt tumors, which are histologically diverse and enriched in a basal-like molecular signature, the majority of Met mt tumors with Trp53 loss displayed a spindloid pathology with a distinct molecular signature that resembles the human claudin-low subtype of TNBC, including diminished claudins, an epithelial-tomesenchymal transition signature, and decreased expression of the microRNA-200 family. Moreover, although mammary specific loss of Trp53 promotes tumors with diverse pathologies, those with spindloid pathology and claudin-low signature display genomic Met amplification. In both models, MET activity is required for maintenance of the claudin-low morphological phenotype, in which MET inhibitors restore cell-cell junctions, rescue claudin 1 expression, and abrogate growth and dissemination of cells in vivo. Among human breast cancers, elevated levels of MET and stabilized TP53, indicative of mutation, correlate with highly proliferative TNBCs of poor outcome. This work shows synergy between MET and TP53 loss for claudin-low breast cancer, identifies a restricted claudin-low gene signature, and provides a rationale for anti-MET therapies in TNBC.
Met RTK | EMT | mouse model | gene expression D espite recent improvements in breast cancer mortality, this disease remains the second leading cause of cancer-related deaths for women worldwide (1) . Gene expression profiling and molecular pathology have revealed that breast cancers naturally divide into luminal A and B, human epidermal growth factor receptor 2 (HER2)-enriched, basal-like, and the recently identified claudin-low subtypes (2, 3) . Targeted therapies that rely on tumor cell expression of estrogen and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ErbB2) receptors can be effective in the treatment of luminal and HER2-positive breast cancers (4) . However, basal-like and claudin-low breast cancers are predominately negative for these receptors, referred to as triple negative (TN), and are associated with poor prognosis. TN breast cancers account for up to 20% of breast cancer cases (5) , emphasizing the need to identify molecular targets for their treatment.
Claudin-low tumors were originally distinguished from other subtypes on the basis of gene expression profiling (3) and have subsequently been correlated with tumors of metaplastic and medullary pathology (6) . These tumors are characterized by loss of tight junction markers (notably claudins) and high expression of markers of epithelial-to-mesenchymal transition (EMT), in addition to being enriched for markers of mammary stem cells (6) .
Signaling through MET, the receptor tyrosine kinase (RTK) for hepatocyte growth factor (HGF) influences diverse cellular processes during both developmental and cancer progression (7, 8) . MET is expressed in the epithelium of numerous tissues, including breast, and regulates cell proliferation, migration, and invasion, as well as EMT (7, 8) . Increased expression of MET is associated with TN breast cancers and correlates with poor outcome (8) (9) (10) (11) . In normal breast, activation of MET in ductal epithelium can occur through paracrine signaling, as a result of the secretion of HGF by stromal fibroblasts, and increased amounts of HGF are detected in serum of patients with breast cancer who have highgrade disease (12, 13) .
Transgenic mice expressing a weakly oncogenic variant of Met under the control of the murine mammary tumor virus (MMTV) Significance Triple-negative breast cancers lack targeted therapies and are subdivided into molecular subtypes, including basal and claudinlow. Preclinical models representing these subtypes are limited. We have developed a murine model in which mammary gland expression of a receptor tyrosine kinase (MET) and loss of tumor suppressor gene p53 (Trp53), synergize to promote tumors with pathological and molecular features of claudin-low breast cancer. These tumors require MET signaling for proliferation, as well as mesenchymal characteristics, which are key features of claudin-low biology. This work associates MET expression and p53 loss with claudin-low breast cancers and highly proliferative breast cancers of poor outcome.
promoter (MMTV-Met mt ), or knock-in of Met mt into its endogenous promoter, develop mammary tumors that are histologically diverse (14, 15) . Consistent with elevated MET in TN breast cancer, 50% of MMTV-Met mt tumors exhibit a molecular signature of the basal-like subclass of human breast cancer and are positive for basal cytokeratins (14, 15) . However, the long latency of the MMTV-Met mt model supports the requirement for cooperating oncogenic events. Loss-of-function mutations in the tumor suppressor gene TP53 (tumor protein p53) are detected in ∼80% of TN breast cancers (2) . Interplay between TP53 and MET is supported by the observation that in a mouse model of mammary tumorigenesis involving Trp53 (murine p53) deletion, 73% of tumors carry amplification of Met (16). Moreover, Met mRNA levels are regulated by the p53-regulated microRNA (miRNA) miR34a (17) . However, synergy between MET and Trp53 loss during mammary tumor formation has not been tested.
To study the consequences of Trp53 loss during MET-induced mammary tumorigenesis, we generated a conditional mouse model in which mammary gland-specific expression of Met (MMTVMet mt ) is combined with Cre-recombinase (MMTV-Cre)-mediated deletion of floxed Trp53 alleles in the mammary gland. We document a significant reduction in tumor latency coupled with a dramatic increase in tumor penetrance in MMTV-Met mt ; Trp53fl/+;Cre mice compared with MMTV-Met mt and a significant increase in penetrance compared with Trp53fl/+;Cre mice. The majority of mammary tumors that arise in MMTV-Met mt ; Trp53fl/+;Cre mice and Trp53fl/+;Cre mice possess a distinctive spindloid pathology, and a comparison of gene expression data with human breast cancer datasets reveals a significant correlation between these mammary tumors and human claudin-low breast cancer. In both cases, the claudin-low phenotype is correlated with amplification of Met and requires continuous MET signaling. This work highlights the fact that MET and TP53 loss act synergistically in promoting breast tumors and provides a model to study the claudin-low subtype. (Table 1) . Unlike the MMTV-Met mt model, in which a spectrum of tumor pathologies was observed (14) , the majority of mammary tumors that arose in MMTV-Met mt ; Trp53fl/+;Cre mice (80%) and, to a lesser extent, in Trp53fl/+;Cre mice (63%) displayed a spindloid pathology, with the remaining tumors being poorly differentiated adenocarcinomas (Fig. 1B) .
Cytokeratin (CK) expression can be used to infer the differentiation status of breast tumors (17, 18) . Interestingly, although nonspindloid MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre adenocarcinomas expressed basal (CK14) and luminal (CK8/18) cytokeratins, as well as CK5 (associated with progenitor cells), spindloid tumors showed only weak and sporadic expression of all CKs tested (CK14, 8/18, 5/6) (Fig. S1A) . Spindloid tumor cells stained strongly for the mesenchymal marker vimentin and were negative for the epithelial marker E-cadherin (Fig. S1 ), which is supportive of an EMT (20) . Interestingly, coexpression of both cytokeratins and vimentin was detected by immunofluorescence in spindloid tumor cells as well as hyperplastic glands (Fig S1B) , thus capturing EMTs. Together, these data support the idea that expression of activated MET in combination with the loss of Trp53 in the mouse mammary gland promotes the formation of tumors with high penetrance and pronounced features that are typical of EMT. (Fig. 1C and Fig. S3 ). Although variable, tumors contained a broad region of amplification at this locus (Chr6 16.7-18.2Mb), which included not only Met but also other genes adjacent to Met; including Cav1 (caveolin 1), Cav2 (caveolin 2), Wnt2 (wingless-related MMTVintegration site 2) and Cftr (cystic fibrosis transmembrane conductance regulator) (Fig. S3) . Notably, amplification of Met was absent in all Trp53fl/+;Cre tumors of adenocarcinoma pathology. The association between Met amplification and Trp53-null mammary tumors of spindloid but not adenocarcinoma-type pathology is highly significant (P = 0.01786), supporting an association between Met amplification and Trp53-deficient tumors with spindle-cell pathology.
Consistent with Met amplification, MMTV-Met mt ;Trp53fl/+; Cre tumors showed strong immunohistochemical staining for the endogenous murine MET protein (Fig. 1D) . In tumors as well as tumor lysates, the murine MET protein was highly phosphorylated on tyrosines 1234/5 (within the activation loop), consistent with its amplification and constitutive activation ( Fig. 1D and (Fig. 1D and Fig. S4 ) and is consistent with suppression of the MMTV promoter after EMT, as shown previously (24) . Notably, Trp53fl/+;Cre spindloid tumors, but not adenocarcinomas, also expressed elevated levels of endogenous murine MET at similar levels of activity to that of MMTV-Met mt ; Trp53fl/+;Cre tumors (Fig. S4) . Thus, genomic amplification of Met leads to constitutive activation of the MET RTK in the absence of its ligand HGF, supporting a potential dependency of these Trp53-deficient mammary tumors on MET signaling. Compared with MMTV-Met mt tumors or normal MFP (Dataset S1, Tables S1-S3), a striking feature of MMTV-Met mt ; Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors was high expression of several markers of the previously determined EMT core signature (Snai1/2, Twist1/2, and Zeb1/2) ( Fig. 2 B and C) (25) , weak expression of cytokeratins as observed by immunohistochemical (IHC) analysis ( Fig. S1 and Fig. 2B ), and decreased representation of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) processes such as cell-cell junction organization, tight junction, and cell junction maintenance ( Fig. 2B and Dataset S1, Tables S4-S7).
Analysis of the genes differentially expressed between MMTVMet mt ;Trp53fl/+;Cre spindloid and MMTV-Met mt tumors also identified enrichment for GO and KEGG categories such as actin filament-based movement and regulation of cell projection organization (Dataset S1, Table S4 and Fig. 2B ), as well as inflammatory response, positive regulation of macrophage chemotaxis, regulation of lymphocyte-mediated immunity, cytokine-cytokine receptor interaction, and chemokine signaling pathway (Dataset S1, Table  S5 ). Consistent with this, high expression of several chemokines and chemokine receptors associated with monocyte and lymphocytic infiltration (Ccr1, Cxcl10, and Cxcl1) (Dataset S1, Table S2 ) (26, 27) Loss of mammary gland expression of Trp53 in the MMTV-Met mt model led to an increase in tumor penetrance and shortened latency, in addition to abrogating the requirement for parity for tumor development. Compared with Trp53fl/+;Cre control mice, MMTV-Met;Trp53fl/+;Cre mice developed tumors with a similar latency but at a significantly higher penetrance, indicating Met expression as an important event in tumor initiation. To determine whether MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre tumors were representative of a subtype of human breast cancer, gene expression profiles were compared with those of Herschkowitz and colleagues (3) . Notably, all MMTVMet mt ;Trp53fl/+;Cre and Trp53fl/+;Cre tumors of spindloid, but not adenocarcinoma, pathology clustered with the claudin-low subclass of human breast cancers (Fig. 3A) . The human claudinlow subclass signature reflects high expression of transcriptional drivers of EMT and low expression of markers of adherens and tight junctions, such as E-cadherin and claudins 1, 3, 4, and 7 (6) . As validated by quantitative RT-PCR, MMTV-Met mt ;Trp53fl/+; Cre and Trp53fl/+;Cre spindloid tumors showed similar expression of genes within this signature, expressing high levels of Snai1/2, Twist1/2, and Zeb1/2 ( Fig. 2C ) and low levels of claudins such as Cldn1,3,4 and 7 and E-cadherin (Fig. 2C) . Importantly, application of a claudin-low subclass gene signature derived from human tumors (6) identified MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+Cre spindloid tumors as strongly correlative (P < 0.0001) (Fig. 3B) . Conversely, application of the differentially expressed gene signature from MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors to human breast cancer subtypes induced a cluster of claudin-low subjects, and this human subtype was found to be highly associated with the signature derived from the murine spindloid tumors (P < 0.0001) (Fig. S6) .
MicroRNA expression profiles are also associated with human breast cancer pathological features and molecular subtypes (31) (32) (33) . Using a signature of ∼50 significantly differentially expressed miRNAs that distinguish claudin-low tumors from other human breast cancer subtypes (33), we identified a near-homogeneous clustering of MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors that were highly associated with the signature (P = 0.0004) (Fig. 3C and Dataset S1, Table S8 ). Notably, consistent with a strong EMT gene expression signature, MMTV-Met mt ; Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors showed a significant decrease in expression of miR-200 family members, whose targets include the transcription factors Zeb1/2 and are known inhibitors of EMT and stemness (34) (35) (36) . Together, these analyses indicate that MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+; Cre spindloid tumors, but not adenocarcinomas, share multiple features in common with human claudin-low breast cancers.
Identification of a Core Claudin-Low Gene Signature. The human claudin-low gene signature constitutes 777 genes (6) . To establish whether a restricted, core claudin-low signature could be identified and whether MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+; Cre spindloid tumors share common features with human claudinlow tumors, we compared genes systematically highly expressed in MMTV-Met mt ;Trp53fl/+;Cre spindloid tumors, Trp53fl/+;Cre spindloid tumors, human claudin-low tumors, and human basal B breast cancer cell lines (Fig. 3D ). This analysis highlighted more than 700 genes that are expressed at elevated levels in either just MMTV-Met mt ;Trp53fl/+;Cre or just Trp53fl/+;Cre tumors, but not the other, a proportional difference that was significantly higher than expected (P = 0.009). When overall gene variance was measured, Trp53fl/+;Cre spindloid tumors were significantly more heterogeneous than MMTV-Met mt ;Trp53fl/+; Cre spindloid tumors (P < 2.2 × 10 −16 ) (Fig. S7) . It is possible that the higher degree of homogeneity observed among MMTV-Met; Trp53fl/+;Cre tumors may result from expression of the MMTVMet transgene at the point of tumor initiation, whereas Trp53-null-alone tumors arise as a result of more stochastic tumorigenic TA899  TA1471  TA65  TA1004  TA646  T5482  TA1129  TA1034  TA1005  TA3571  TA2843  TA4716  TA3957  TA4328  TA4719_23L  TA3340  TA4504  TA4719_1L  TA2244  T6696  T5156  T6030  T5033  TA66  TA1221  T4425  T5154  TA4375_3R  T4695  TA4375_23R  N6030  NA66  N4425  NA1222  NPOOL31  NPOOL16  NPOOL15  NA1471  NPOOL30  NPOOL32 (Mixed)   TA1129  TA899  TA1005  T5482  TA4719_1L  TA1471  TA3340  TA3571  TA2244  TA1034  TA4719_23L  TA3957  TA4504  T4425  TA4375_23R  T4695  T5154  TA1221  TA4375_3R  T6030  T5156  TA66  TA1349 Claudin-low low miRNA
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In addition to differences, this analysis generated an intersect containing 36 genes in common among MMTV-Met mt ;Trp53fl/+; Cre spindloid tumors, Trp53fl/+;Cre spindloid tumors, human claudin-low tumors, and human basal B breast cancer cell lines (Fig. 3D) . Consistent with the highly mesenchymal phenotype of our murine as well as human claudin-low tumors, the core 36-gene intersect includes genes linked to EMT (Twist1, Zeb2, and Vim) in addition to actin cytoskeleton dynamics (Fscn1) (37), extracellular matrix interaction, and cell migration (Msn, lamb1, and Itga5) (38, 39) (Fig. 3 D and E) . The 36-gene intersect also included the proinflammatory cytokine Il-18 and genes associated with poor-outcome breast cancers [Vegfc (40) and Ybx1 (41)]. To test whether the 36-gene intersect alone could identify human claudin-low tumors, we applied it to a human breast cancer dataset containing claudin-low patients (6) . Compared with the published claudin-low predictor of Prat et al. (6) , which includes 426 genes with elevated expression and 351 genes with decreased, the 36-gene intersect, which represents a small subset, identified claudin-low patients with an equivalent degree of accuracy as the published predictor (Fig. S8) (P < 0.0001) . Thus, our 36-gene set is functionally equivalent at identifying human claudin-low tumors while elucidating core aspects of claudin-low biology, including potential biomarkers.
Claudin-Low EMT Phenotype Is Dependent on MET Kinase. Met was identified within the intersect of MMTV-Met mt ;Trp53fl/+;Cre tumors, Trp53fl/+;Cre tumors, and basal B-cell lines (Dataset S1, Table S9 ) and is also retained as part of the published claudin-low predictor (6) . To establish whether MET is involved in the maintenance of claudin-low characteristics, primary cells from MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors, which amplify the endogenous Met locus and maintain a strong EMT morphology in culture, were treated with two small-molecule MET-kinase inhibitors (PHA665752 and Crizotinib) (Fig. S9) . On inhibition of MET kinase activity, a striking change in cell morphology was observed in both MMTV-Met mt ; Trp53fl/+;Cre and Trp53fl/+;Cre tumor cells. Cells lost their elongated mesenchymal morphology, formed cell-cell junctions positive for the tight junction marker zona occludens protein 1 (ZO-1), and remodeled their actin cytoskeleton with enhanced appearance of cortical actin (Fig. 4A) . Consistent with the formation of cell-cell junctions and the loss of the EMT morphological phenotype, elevated levels of Claudin 1 protein (CLDN1) were observed (Fig. 4B) , as well as an elevation in Cldn1 (Claudin 1) and Cdh1 (E-cadherin) mRNA (Fig. 4C ). In contrast, and surprisingly, mRNA levels of EMT transcriptional drivers Snail, Twist, and Zeb were not significantly reduced (Fig.  4D ). This demonstrates that continued MET signaling has an important role in regulating cell-cell junction disassembly, even in the presence of high levels of key EMT regulators, a characteristic of claudin-low tumor pathology.
In addition to restoring tight junctions and reverting the mesenchymal cell morphology, MET inhibition resulted in significantly impaired proliferation of both MMTV-Met mt ;Trp53fl/+; Cre and Trp53fl/+;Cre spindloid tumor cells, both under normal (adherent) growth conditions and in soft agar (Fig. 5 A-C) . In addition, Annexin V and propidium iodide labeling revealed a significant decrease in the viability of cells that had been treated for 48 h with either PHA665752 or Crizotinib (Fig. 5 D and E) . Together, these data support that both MMTV-Met cells introduced via the tail vein bypass the normal metastatic cascade and are delivered directly to the lung, only rarely being detected in other organs (42) (43) (44) . Notably, daily treatment of injected mice with the orally available MET inhibitor Crizotinib (45 mg·kg
) significantly reduced metastatic growth both in the lungs and livers of the mice (Fig. 6) , showing that the metastatic growth of these EMT mammary tumor cells is highly dependent on MET activity.
Elevated MET and TP53 Protein Correlates with Hormone Receptor-
Negative Status and Poor Prognosis in Human Breast Cancer. Alterations in TP53 are typically associated with the basal subtype of TN breast cancer (2) . Missense mutations are associated with increased stability of the TP53 protein and can be detected by IHC analysis, as significantly higher tumor tissue staining is observed compared with tumors with TP53 truncating mutations or wild-type TP53 (45). Overexpression of MET and expression of mutant TP53 proteins have both been shown to have prognostic value individually; however, the significance of their coexistence in the same tumor has not been examined. The examination of MET and TP53 protein in a cohort of 618 axillary lymph nodenegative human breast cancer cases (46) revealed that tumor epithelium was positive for MET immunostaining and/or TP53 staining, with an absence of staining in the stroma (Fig. 7A) . Tumors that stained strongly for MET were more likely to be TP53 positive than those negative for MET, as 13.9% of all 618 tumors studied were MET+/TP53+ compared with 9.1% that were MET−/TP53+ (Fig. 7B) (P < 0.0001).
Tumors that scored for both high MET and TP53 were observed in all histological subtypes, but a significantly greater proportion of MET/TP53 copositive tumors were estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and CK5-positive (61%, 71%, and 44%, respectively) than tumors with other combinations of MET and TP53 (24%, 38%, and 14%, respectively; P < 0.0001) (Dataset S1, Table S11 ). Basal, TN phenotype (TNP)-nonbasal, Her2, and luminal subtypes were determined as previously described (47) . MET/P53 copositive tumors were found to correlate most significantly with the basal (P < 0.0001) and TNP-nonbasal (P = 0.0211) subtypes (Table 2 ). More precise identification of claudin-low patients would require an examination of a claudin-low gene expression signature within this set and/or the use of a positive IHC marker for claudin-low, which is currently not known. However, on the basis of the available information for this cohort, both of these subtypes could include patients of claudin-low pathology.
The majority of MET/TP53-positive tumors (94%) scored high for cell proliferation marker KI67 compared with 57% for other combinations of MET and TP53 (P < 0.0001) (Dataset S1, Table  S11 ). Consistent with this, combined MET/TP53-positive tumor status correlates with poor disease-free survival among lymph node-negative patients ( Fig. 7C ; log rank P = 0.0012) compared Late apoptotic/ dead with patients with other combinations of MET/TP53 status, demonstrating that the combination of elevated MET with positive TP53 IHC is a strong predictor of poor outcome. This association persisted in multivariate analysis after adjustment for traditional histopathological prognostic factors (Dataset S1, Tables S11 and S12). Finally, MET/TP53 copositivity can also identify poor-outcome patients within the TN group alone (Fig. 7D) . Together, these results strongly support a role for MET/TP53 signaling in human ER/PR-negative, CK5-positive breast cancers and in breast cancers with high KI67 staining and poor outcome.
Discussion
One of the challenges for the effective treatment of breast cancer is the heterogeneity of the disease (48) . TN breast cancers alone encompass at least 2 (and potentially 6, some of which are more recently identified) (49) molecular subtypes referred to as basallike and claudin-low (3, 6) , for which there are a lack of known therapeutic targets and suitable animal models. Evidence supports that the MET RTK is elevated in human TN breast cancers (8) . This, together with the observation that murine models expressing a weakly activated Met in the mammary epithelium develop tumors with basal-like characteristics, supports a role for MET in the development of basal-like mammary tumors (14, 15) . However, the involvement of MET in other subtypes within TN or the ability of MET to synergize with known alterations in TN breast cancer has not been addressed. To create a more accurate model for human TN breast cancer, we have exploited the frequent occurrence of TP53 mutations in TN breast cancer and generated a model combining expression of a weakly oncogenic MET receptor (MMTV-Met mt ) (14) (6) . Key aspects include enrichment for a claudinlow gene expression signature (P < 0.0001) (6) and miRNA signature, including loss of Claudin gene expression (e.g., Cldn1, Cldn3, Cldn4, and Cldn7), expression of the core EMT gene signature (Snai1/2, Twist1/2, and Zeb1/2), and lymphocytic infiltration (6, 23) . This phenotype is shared by 5/8 Trp53fl/+;Cre tumors, which, in addition to loss of Trp53, show amplification of Met and a similar claudin-low gene expression signature to MMTV-Met mt ; Trp53fl/+;Cre spindloid tumors. In contrast, MMTV-Met mt tumors clustered with basal and luminal subtypes (14) , and only a single MMTV-Met mt tumor with a spontaneous Trp53 mutation, expressed a claudin-low signature (Fig. 3B) . One important difference within Trp53fl/+;Cre tumors is that Met amplification was not detected in Trp53fl/+;Cre tumors of adenocarcinoma pathology. This indicates that loss of Trp53 alone, as evident in Trp53fl/+; Cre adenocarcinomas, is insufficient for spindloid pathology and a penetrant claudin-low phenotype and supports a synergistic role for Met, together with Trp53 loss, in promoting tumors with a spindloid pathology and claudin-low molecular subtype in the FVB background. This is consistent with the enhanced penetrance (70%) and high incidence of spindloid (80%), claudin-low-type tumors in MMTV-Met (Fig. S3A) .
The mechanism selecting for Met amplification in the Trp53fl/+; Cre FVB model is unclear. A similar amplification of Met is observed in 73% of mammary tumors involving germ-line loss of Trp53 in combination with a conditional breast cancer 1 (Brca1) mutation (Brca1 (Fig. S12) . Moreover, these cell lines are continuously dependent on MET signaling for their EMT phenotype, as well as for their proliferation and survival both in culture and in vivo. Thus, Met amplification with consequent constitutive activation of the kinase is required to maintain the claudin-low mesenchymal phenotype of these cells. The unstable nature of the Met amplicon in the Brca1 Δ11/co ;MMTV-Cre;Trp53 +/− model may reflect loss of function of Brca1, which contributes to chromosomal instability, whereas we observe no decrease in Brca1 or Brca2 expression in MMTV-Met;Trp53fl/+;Cre tumors compared with normal mammary gland (Dataset S1, Table S2 ). Interestingly, an amplicon containing Met was also recently detected in murine mammary tumors that arise as a result of potentiated Notch signaling and that also model both basal-like and claudin-low breast cancers (51) . Although the stability of this amplicon was not addressed in this study, this lends further support for a specific role for MET signaling in murine models of claudin-low breast cancer.
Cell explants derived from MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid claudin-low-like tumors retain a mesenchymal phenotype that is highly dependent on continued MET signaling. When treated with two pharmacological MET inhibitors, a reversal of the EMT morphological phenotype was observed, with elevated levels of Claudin 1 and reformation of ZO-1 positive cell-cell junctions, which are claudin-dependent (52) . Although the effect of MET signaling on tight junction disassembly is clear, we observed no changes in the mRNA levels of the core transcriptional drivers of EMT (Snai1/2, Twist1/2, and Zeb1/2) on MET inhibition (Fig. 4) , demonstrating that continued MET activation is essential to maintain the EMT morphological phenotype and the loss of claudin gene expression, a hallmark of human claudin-low tumors (6) .
Although MET can promote elevated expression of Zeb1 and Snail to initiate EMT (14) , the core EMT signature is elevated in Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre spindloid tumors compared with MMTV-Met mt basal subtype tumors. This likely reflects the role for wild-type Trp53 in promoting an epithelial phenotype through transcriptional activation of the miR-200 family (underexpressed within the human claudin-low miRNA signature) that negatively regulates the key regulators of EMT (34) . Consistent with this, after loss of Trp53 in MMTV-Met mt ; Trp53fl/+;Cre and Trp53fl/+;Cre tumors, we observe a decrease in the miR-200 family and correspondingly high levels of EMT transcriptional drivers that are not altered after MET inhibition.
Accumulating evidence supports a role for MET and METdependent signals in human claudin-low breast cancer. MET contributes to a published claudin-low predictor (6) . A strong MET signaling network is present in both MMTV-Met (Fig. 3E) . The selection for amplification of the Met locus in Trp53-null tumors of spindloid pathology is striking and highlights an emerging concept in cancer whereby genes that function synergistically to enhance signaling will frequently be coselected during tumor formation or progression.
We propose that Met synergizes in this context with loss of function of Trp53 but may also synergize with other regulators of this phenotype such as Notch (51) . The observed amplification of genes also amplified in human basal and claudin-low breast cancer such as Caveolin 1 and Myc in the MMTV-Met mt ;Trp53fl/+; Cre model provides a valuable tool to understand the molecular events and signaling pathways that drive TN breast cancers. This model also presents an opportunity to study the tumor microenvironment of claudin-low breast cancer, as demonstrated by the evidence for robust leukocyte infiltration. Because human claudin-low breast cancer is especially difficult to treat due to the lack of biomarkers, determining molecular targets that can be used in drug therapy is of utmost importance. In addition, because small-molecule MET inhibitors are presently in clinical trials for multiple cancers, this raises the possibility that TP53 status may be important for patient selection.
Materials and Methods
Transgenic Mice. MMTV-Met mt mice were described previously (14) . MMTV-Cre mice were generated in the laboratory of W.J. Muller (55) . Mice with floxedTrp53 alleles are described elsewhere (21), were obtained from the National Cancer Institute mouse repository, and were bred onto a pure FVB background. Mice were housed in accordance with McGill University Animal Ethics Committee guidelines.
Immunohistochemical and Immunofluorescent Analyses of Mouse Tissue and Cell Lines. Cells were fixed and histology samples prepared as described in SI Materials and Methods. Primary and secondary antibodies are detailed in Dataset S1, Table S13 .
Microarray Data. Gene expression profiles were generated using Agilent 4 × 44K whole-mouse genome gene expression microarrays. Copy number gains and losses were assessed using Agilent 4 × 44K whole-mouse genome CGH arrays. miRNA profiling was performed using the Agilent 8 × 15K mouse miRNA platform. Raw and normalized microarray data have been deposited in the Gene Expression Omnibus database under accession no. GSE41748. All analyses are detailed in the SI Materials and Methods.
Isolation and Culture of Mouse Mammary Tumor Cells. Primary cells were isolated from mouse mammary tumors as described (56) . Cells were cultured Scoring for MET and TP53 IHC on a human breast cancer tissue microarray was correlated with subtype. Breast cancers that stained positively for both MET and TP53 were more likely to be classified as basal, than breast cancers with other combinations of MET and TP53 staining (30.2% vs. 7.9%). Likewise, more MET/TP53 copositive breast cancers were classified as TNPnonbasal, than breast cancers positive to MET or TP53 alone (7.0% vs. 2.0%).
in DMEM supplemented with 5% (vol/vol) serum, epidermal growth factor (5 ng/mL), insulin (5 μg/mL), bovine pituitary extract (35 μg/mL), and hydrocortisone (1 μg/mL).
Met Inhibition. MMTV-Met mt ;Trp53fl/+;Cre and Trp53fl/+;Cre tumor cell lines were treated with PHA665752 (Pfizer) or Crizotinib (LC Laboratories) at a final concentration of 1 μM. Control cells were incubated with an equivalent concentration of DMSO alone for the same amount of time.
